CTRL Therapeutics is a biotechnology company developing a next-generation cell therapy platform with the potential to unlock a new frontier in cell therapy for solid tumors. With broad applicability across numerous solid tumors, the company's proprietary approach for the identification and isolation of circulating tumor-reactive lymphocytes (cTRLs) has the potential to address longstanding challenges associated with cell therapy and offers key advantages over tumor-infiltrating lymphocytes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/10/23 | $10,000,000 | Seed |
FACIT General Catalyst Partners  Intermountain Healthcare | undisclosed |
